In mid-July, Nestlé announced its investment in a company called Accera, which develops “brain health shakes” for Alzheimer’s patients. Nestlé did not comment on the size of its investment, but said Luis Cantarell, president and CEO of Nestlé Health Science S.A., would join the company’s board of directors.
According to Accera, this investment will help further clinical development and commercialization of Axona, a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s Disease (AD).
“Nestlé Health Science’s investment will enable us to make larger clinical trials and help us strengthen our commercial capabilities in the U.S.,” said Holger Kunze, president and CEO of Accera. “It will also provide an opportunity to expand the geographic footprint of Axona longer-term.”
Mr. Cantarell stated, “Given Axona’s proven mode of action and the significant experience of Accera’s management team, I believe we can make a difference in people’s lives by providing AD patients with an innovative solution. This investment is a good fit with our vision for the brain health space.”